Physician profile
Stefan C Weiss
NPI 1578641387
$621,840.05
in general payments reported to CMS, 2019-2025
23 companies · $115K in 2025
The $115K reported for 2025 was more than what 98% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228K · 2020: $48K · 2021: $45K · 2022: $57K · 2023: $68K · 2024: $61K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Consulting Fee: $33K · Travel and Lodging: $26K · Food and Beverage: $8,398 · Education: $173 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,110.25 |
| Consulting Fee | $33,137.50 |
| Travel and Lodging | $25,665.95 |
| Food and Beverage | $8,398.39 |
| Education | $172.94 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370,956.09 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135,800.31 | 2019-2022 | |
| Galderma Laboratories, L.P. | $39,730.81 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $25,658.28 | 2023-2025 | Zoryve |
| Almirall LLC | $25,000.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12,033.80 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $5,940.63 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $5,736.52 | 2023-2025 | Anzupgo, Adbry, Spevigo |
| Incyte Corporation | $272.63 | 2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $160.18 | 2023-2025 | |
| Ucb, INC. | $127.38 | 2023-2025 | Bimzelx, Cimzia |
| Organon LLC | $105.67 | 2025 | Vtama |
| Genzyme Corporation | $73.71 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $54.92 | 2023-2024 | Dupixent, Libtayo |
| Lilly USA, LLC | $39.36 | 2024-2025 | Ebglyss, Taltz, Olumiant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.56 | 2024 | Sotyktu |
| Merz North America, INC. | $30.32 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2024 | Spevigo |
| Janssen Biotech, INC. | $17.23 | 2025 | Stelara, Tremfya, Simponi |
| Biofrontera INC. | $15.93 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Convatec INC. | $15.07 | 2024 | |
| Pfizer INC. | $13.83 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.